Abstract:At present, the production of influenza vaccine is mainly based on chicken embryo vaccine, and the problem is still in the selection of candidate vaccine strain. The mammalian cell-based vaccine is well matched with the epidemic virus, so the protection effect is stronger than the chicken embryo. However, due to inadequate facilities and other reasons, the current production of the cell-based vaccine cannot be compared with the chicken embryo vaccine. Therefore, the selection of seasonal influenza vaccine strain should be improved on the basis of chicken embryo vaccine. The definition of high risk population is still based on the WHO, but in children and the population of young people are different, and the general sensitive population can also be vaccinated. The universal vaccine is still in the research stage, people should not expect too much on it.
严延生. 流感疫苗的研究进展[J]. 中国人兽共患病学报, 2018, 34(8): 677-683.
Yan Yan-sheng. Research progress of influenza vaccine. Chinese Journal of Zoonoses, 2018, 34(8): 677-683.
[1] Palese P.Influenza: old and new threats[J]. Nat Med,2004,10:S82-87. [2] Hause BM, Collin EA, Liu R, et al.Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family[J]. MBio,2014:5:e00031-14. [3] World Health Organization. Ask the expert: Influenza Q&A[EB/OL].(2018-01-31)[2018-04-28].http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal [4] Wu Y, Wu Y, Tefsen B, et al.Bat-derived influenza-like viruses H17N10 and H18N11[J]. Trends Microbiol, 2014,22(4):183-191.DOI:10.1016/j.tim.2014.10.010 [5] Wilson JR, Guo Z, Reber A, et al.An influenza a virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo[J]. Antivir Res,2016,135:48-55.DOI:10.1016/j.antiviral.2016.10.001 [6] Freidl GS, Meijer A, de Bruin E, et al.Influenza at the animal-human interface: a review of the literature for virological evidence of human infection with swine or avian influenza viruses other than a(H5N1)[J]. Euro Surveill, 2014,19(18):20793.DOI:10.2807/1560-7917.ES2014.19.18.20793 [7] Centers for Disease Control and Prevention. Selecting Viruses for the Seasonal Influenza Vaccine[EB/OL].[2018-05-21]. https://www.cdc.gov/flu/ [8] Centers for Disease Control and Prevention. How Influenza (Flu) Vaccines Are Made[EB/OL].[2018-06-27]. https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made. [9] McLean KA, Goldin S, Nannei C, et al. The 2015 global production capacity of seasonal and pandemic influenza vaccine[J]. Vaccine, 2016,34(45)5410-5413.DOI:10.1016/j.vaccine.2016.08.019 [10] Ping J, LopesTJ, Nidom CA,et al. Development of high-yield influenza a virus vaccine viruses[J]. Nat Commun,2015,6: 8148.DOI:10.1038/ncomms9148 [11] Wong SS,Webby RJ.Traditional and new influenza vaccines[J]. Clin Microbiol Rev,2013,26:476-492.DOI:10.1128/CMR00097-12 [12] Centers for Disease Control and Prevention. How Influenza (Flu) Vaccines Are Made. [EB/OL]. (2018-02-12)[2018-05-18]. https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm [13] Weir JP. Food and Drug Administration Supplement Approval.2016[EB/OL]. (2016-09-23)[2018-08-14]https://www.fda.gov/default.htm [14] Skowronski DM,Janjua NZ,De Serres G, et al.Low 2012-2013 influenza vaccine effectiveness associated with mutation in the egg-adapted h3n2 vaccine strain not antigenic drift in circulating viruses[J]. PLoS one,2014,9(3):e92153.DOI:10.1371/journal.pone.0092153 [15] World Health Organization (WHO). Addendum to the Recommended Composition of Influenza Virus Vaccines for Use in the 2003-2004 Influenza Season[EB/OL].[2018-08-14].http://www.who.int/ [16] Centers for Disease Control and Prevention. 2003-2004 U.S. Influenza Season Summary[EB/OL]. [2018-02-12](2018-05-06). https://www.cdc.gov/flu/weekly/weeklyarchives2003-2004/03-04summary.htm [17] Nicholls JM,Chan RW,RussellRJ, et al. Evolving complexities of influenza virus and its receptors[J].Trends Microbiol, 2008,16(4):149-157. DOI:10.1016/j.tim.2008.01.008 [18] Imai M, Kawaoka Y.The role of receptor binding specificity in interspecies transmission of influenza viruses[J]. Curr Opin Virol,2012, 2:160-167.DOI:10.1016/j.coviro.2012.03.003 [19] Cobey S, Hensley SE.Immune history and influenza virus susceptibility[J]. Curr Opin Virol, 2017,22:105-111.DOI:10.1016/j.coviro.2016.12.004 [20] Zost SJ, Parkhouse K, Gumina ME, et al.Contemporary H3N2 influenza viruse s have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains[J]. PNAS ,2017,114(47):12578-12583.DOI:10.1073/pnas.1712377114 [21] Paules CI,Sullivan SG, Subbarao K,et al.Chasing seasonal influenza—The need for a universal influenza vaccine[J]. N Engl J Med, 2018,378: 7-9.DOI: 10.1056/NEJMp1714916 [22] Flannery B,Chung JR,Belongia EA,et al.Interim estimates of 2017-2018 seasonal influenza vaccine effectiveness—United States, February 2018[J]. MMWR,2018,67(6): 180-185.DOI: 10.15585/MMWR.MM6706a2 [23] Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2005-2018[EB/OL].[2018-08-14].https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm [24] Centers for Disease Control and Prevention. Cell-Based Flu Vaccines[EB/OL]. (2018-02-12)[2018-05-06]. https://www.cdc.gov/flu/protect/vaccine/cell-based.htm [25] Hegde NR.Cell culture-based influenza vaccines: A necessary and indispensable investment for the future[J]. Hum Vaccines Immunother, 2015,11(5):1223-1234.DOI:10.1080/21645515.2015.1016666 [26] Milián E,Kamen, AA. Current and emerging cell culture manufacturing technologies for influenza vaccines[J].BioMed Res Int 2015,2015: 504831. DOI: 10.1155/2015/504831 [27] Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Supply for the U.S. 2017-2018 Influenza Season[EB/OL]. (2018-03-19)[2018-05-06]. https://www.cdc.gov/flu/about/qa/vaxsupply.htm [28] Centers for Disease Control and Prevention. Flublok Seasonal Influenza (Flu) Vaccine[EB/OL]. (2018-02-12)[2018-05-06]. https://www.cdc.gov/flu/protect/vaccine/qa_flublok-vaccine.htm [29] Cox M M,Hashimoto Y.A fast track influenza virus vaccine produced in insect cells[J]. J Invertebr Pathol,2011,107:S31-S41.DOI:10.1016/j.jip.2011.05.003 [30] Buckland B,Boulanger R,Fino M,et al.Technology transfer and scale-up of the flublok recombinant hemagglutinin (ha) influenza vaccine manufacturing process[J]. Vaccine,2014,32:5496-5502.DOI:10.1016/j.vaccine.2014.07.074 [31] NCIRD. Archived CDC Vaccine Price List as of 2 February 2017>[EB/OL]. (2018-02-22)[2018-05-06].https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/2017/2017-02-02.html [32] Centers for Disease Control and Prevention. Flublok Seasonal Influenza (Flu) Vaccine. [EB/OL].(2018-02-12)[2018-05-06].https://www.cdc.gov/flu/protect/vaccine/qa_flublok-vaccine.htm [33] Centers for Disease Control and Prevention. Fluad Flu Vaccine with Adjuvant[EB/OL]. (2018-03-20)[2018-05-06]. https://www.cdc.gov/flu/protect/vaccine/adjuvant.htm [34] WHO. Squalene-Based Adjuvants in Vaccines[EB/OL].(2018-03-20)[2018-05-06]. http://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/ [35] Cruz-Valdez, A,Valdez-Zapata, G,Patel, SS,et al.Mf59-adjuvanted influenza vaccine (fluad(r)) elicits higher immune responses than a non-adjuvanted influenza vaccine (fluzone(r)): A randomized, multicenter, phase iii pediatric trial in Mexico[J].Hum Vaccines Immunother 2018,14(2): 386-395. 10.1080/21645515.2017.1373227 [36] Harding AT,Heaton BE,Dumm RE,et al.Rationally designed influenza virus vaccines that are antigenically stable during growth in eggs[J]. mBio,2017,8:e00669-17.DOI:10.1128/mBio.00669-17 [37] Widjaja L,Ilyushina N,Webster RG,et al.Molecular changes associated with adaptation of human influenza a virus in embryonated chicken eggs[J]. Virology,2006,350(1):137-145.DOI:10.1016/j.viro.2006.02.020 [38] Lu B, Zhou H, Ye D,et al.Improvement of influenza a/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics[J]. J Virol, 2005,79:6763-6771.DOI:10.1128/JVL79.11.6763-6771.2005 [39] Nicolson C,Major D,Wood JM,et al.Generation of influenza vaccine viruses on vero cells by reverse genetics: An H5N1 candidate vaccine strain produced under a quality system[J]. Vaccine,2005, 23,2943-2952. DOI:10.1016/j.vaccine.2004.08.054 [40] Smith G,Liu Y,Flyer D,et al.Novel hemagglutinin nanoparticle influenza vaccine with matrix-adjuvant induce shem agglutination inhibition, neutralizing and protective responses in ferrets against homologous and drifted a(H3N2) subtypes[J].Vaccine,2017, 35(40): 5366-5372.DOI:10.1016/j.vaccine.2017.08.021 [41] Kanekiyo M,Wei CJ,Yassine, HM,et al.Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies[J]. Nature,2013, 499, 102-106. DOI: 10.1038/nature12202 [42] Quan FS,Lee YT, Kim KH,et al.Progress in developing virus-like particle influenza vaccines[J]. Expert Rev Vaccines, 2016,15(10): 1281-1293. DOI:10.1080/14760584.2016.1175942 [43] Aguilar JC,Rodriguez EG.Vaccine adjuvants revisited[J].Vaccine, 2007, 25(19):3752-3762. DOI:10.1016/j.vaccine.2007.01.111 [44] Sercombe L,Veerati T,Moheimani F,et al.Advances and challenges of liposome assisted drug delivery[J]. Front Pharmacol,2015, 6:286. DOI:10.3389/fphar.2015.00286 [45] Moser C,Muller M, Kaeser MD, et al.Influenza virosomes as vaccine adjuvant and carrier system[J]. Expert Rev Vaccines,2013, 12(7):779-791. DOI:10.1586/14760584.2013.811195 [46] Ma JH,Yang FR,Yu H,et al.An m2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge[J]. Virol J, 2013, 10:227.DOI:10.1186/1743-422x-10-227 [47] Shen X,Soderholm J,Lin F,et al.Influenza A vaccines using linear expression cassettes delivered via electroporation afford full rotection against challenge in a mouse model[J].Vaccine,2012,30(48):6946-6954. DOI:10.1016/j.vaccine.2012.02.071 [48] Petsch B,Schnee M,Vogel AB,et al.Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection[J]. Nat Biotechnol,2012, 30(12):1210-1216.DOI:10.1038/nbt.2436 [49] Redding L,Weiner DB.DNA vaccines in veterinary use[J]. Expert Rev Vaccines, 2009, 8: 1251-1276. DOI:10.1586/erv.09.77 [50] Ranjan P,Bowzard JB,Schwerzmann JW,et al.Cytoplasmic nucleic acid sensors in antiviral immunity[J]. Trends Mol Med,2009,15(8): 359-368. DOI:10.1016/j.molmed.2009.06.003 [51] Cho A,Wrammert J.Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine[J]. Currt Opin Virol, 2016,17: 110-115. DOI:10.1016/j.coviro.2016.03.002 [52] Soema PC,Kompier R,Amorij JP,et al.Current and next generation influenza vaccines: Formulation and production strategies[J]. Eur J Pharm Biopharm, 2015,94: 251-263.DOI:10.1016/j.ejpb.2015.05.023 [53] Toussi D,Massari P.Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands[J]. Vaccines, 2014, 2(2): 323-53. DOI:10.3390/vaccines2020323 [54] Fiore AE, Uyeki TM, Broder K,et al.Prevention and control of influenza with vaccines: recommendations of the Advisory Committeeon Immunization Practices(ACIP),2010[J].MMWR Recomm Rep , 2010,59(RR8):1-62. [55] Mereckiene J, Cotter S, Nicoll A, et al.National seasonal influenza vaccination survey in Europe[J].Euro Surveill, 2008,13(43):19017. DOI:10.2807/ese.13.43.19017-en [56] Osterholm MT, Kelley NS, Sommer A, et al.Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2012,12:36-44.DOI:10.1016/S1473-3099(11)70295-x [57] Sautto GA,Kirchenbaum GA,Ross TM.Towards a universal influenza vaccine: Different approaches for one goal[J]. Virol J, 2018,15(17):1-12.DOI:10.1186/s12985-017-0918-y [58] Nachbagauer R, Krammer F.Universal influenza virus vaccines and therapeutic antibodies[J].Clin Microbiol Infect,2017, 23(4):222-228.DOI:10.1016/j.cmi.2017.02.009